Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Products under Development by Stage of Development | 7 | 1 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Products under Development by Therapy Area | 8 | 1 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Products under Development by Indication | 9 | 1 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Products under Development by Companies | 12 | 2 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Products under Development by Universities/Institutes | 14 | 2 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutics Assessment | 16 | 6 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 2 |
| Assessment by Route of Administration | 19 | 1 |
| Assessment by Molecule Type | 20 | 2 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Companies Involved in Therapeutics Development | 22 | 4 |
| AFFiRiS AG | 22 | 1 |
| ChemoCentryx, Inc. | 23 | 1 |
| Dompe Farmaceutici S.p.A. | 24 | 1 |
| Prommune, Inc. | 25 | 1 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Drug Profiles | 26 | 11 |
| avacopan Drug Profile | 26 | 5 |
| DF-2593A Drug Profile | 31 | 1 |
| Drug to Antagonize C5aR for Periodontitis Drug Profile | 32 | 1 |
| EP-67 Drug Profile | 33 | 1 |
| Small Molecule to Target C5aR for Undisclosed Indication Drug Profile | 34 | 1 |
| Synthetic Peptide to Antagonize C5aR for Amyotrophic Lateral Sclerosis Drug Profile | 35 | 1 |
| Vaccine to Target C5a for Alzheimer's Disease Drug Profile | 36 | 1 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Dormant Projects | 37 | 2 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Discontinued Products | 39 | 1 |
| C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Featured News &Press Releases | 40 | 16 |
| Jul 13, 2016: UNMC Researcher Secures $2.25 Million Grant to Fight Antibiotic Resistance | 40 | 1 |
| Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development | 40 | 2 |
| Jun 01, 2016: ChemoCentryx Receives European Medicines Agency Priority Medicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis | 42 | 1 |
| May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress | 43 | 2 |
| Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis | 45 | 1 |
| Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 | 46 | 1 |
| Nov 05, 2015: ChemoCentryx Presents Phase II Results on CCX168 at the American Society of Nephrology Annual Meeting | 47 | 1 |
| Aug 19, 2015: UNMC spinoff company to test H1N1 vaccine in animal trial | 48 | 1 |
| Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vascul... | 49 | 1 |
| Nov 20, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in Atypical Hemolytic Uremic Syndrome Treatment by the FDA | 49 | 1 |
| Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements | 50 | 1 |
| Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA | 51 | 1 |
| Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements | 51 | 1 |
| Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis | 52 | 2 |
| Dec 07, 2012: Penn-Led Research Suggests A New Strategy To Prevent Or Halt Periodontal Disease | 54 | 2 |
| Appendix | 56 | 2 |
| Methodology | 56 | 1 |
| Coverage | 56 | 1 |
| Secondary Research | 56 | 1 |
| Primary Research | 56 | 1 |
| Expert Panel Validation | 56 | 1 |
| Contact Us | 56 | 1 |
| Disclaimer | 57 | 1 |
